Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study.

PLoS One · 2024 · PMC10942024 · PMID 38489314

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0970

boldest claim

The sentences

borderline significantp-value = 0.07so close (0.05 < p ≤ 0.1)

However, borderline significant results were observed when comparing the ‘tonabersat 5/7’ with the ‘tonabersat during radiotherapy’ group (p-value = 0.07).

also in 11,409 other papers

a trend toward significancep-value = 0.097so close (0.05 < p ≤ 0.1)

Also, it is worth mentioning that the addition of tonabersat to radiotherapy resulted in a prolonged survival time, with a trend toward significance (p-value = 0.097) compared to the use of TMZ in conjunction with radiotherapy (i.e., ‘control’ group).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.